What is it about?
Glioblastoma multiforme (GBM) is an aggressive and malignant type of brain tumor which commonly presents at higher stages of cancer. This review highlights current findings on GBM biomarkers (e.g. MGMT, EGFRvIII, IDH) and how patients with different biomarkers may respond different towards various treatment options.
Featured Image
Why is it important?
This review serves as a summary of recently studied functional biomarkers of GBM which may serve as to predict disease progression and even stratify patients. Recent GBM therapy advances which include gene therapy and immunotherapy are also discussed. These may guide future studies in properly elucidating GBM disease progression and possibly in developing an effective cure for it.
Perspectives
Although there is currently no available functional cure for GBM, the disease is continuously being studied. With this article, I hope that more attention would be called upon in pouring more time and resources for GBM research and studies of nervous system cancers in general. As technical as the article may seem, it was exciting to write this article, as molecular neuroscience is my passion, and I wish that it also gives readers a new molecular insight on neuroscience and cancer research in general.
Mr Andrew Octavian Sasmita
International Medical University
Read the Original
This page is a summary of: Biomarkers and therapeutic advances in glioblastoma multiforme, Asia-Pacific Journal of Clinical Oncology, August 2017, Wiley,
DOI: 10.1111/ajco.12756.
You can read the full text:
Resources
Contributors
The following have contributed to this page
